Evidence map›Paper›PMID 22405322›Full record

ArticleBMC infectious diseases2012

Proportion of extended-spectrum ß-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon.

Carine Magoué Lonchel, Cécile Meex, Joseph Gangoué-Piéboji, Raphaël Boreux, Marie-Claire Okomo Assoumou, Pierrette Melin, Patrick De Mol

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Prevalence of extended-spectrum-β-lactamase-producingAntimicrobial resistance and infection control · 2018
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Characteristics ofJournal of pathogens · 2022
    Article
  13. Article
  14. Article
  15. Prevalence of Extended-SpectrumInternational journal of microbiology · 2021
    Review
  16. Intestinal Carriage of Extended-SpectrumThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021
    Article
  17. Antimicrobial Resistance inFrontiers in medicine · 2021
    Review
  18. Carriage of Extended-Spectrum-The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2020
    Article
  19. Article
  20. Fecal carriage of extended-spectrum β-lactamase-producingAntimicrobial resistance and infection control · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Carine Magoué LonchelLaboratory of Medical Microbiology, University of Liège, CHU Sart-Tilman (B23), B-4000 Liege, Belgium. macarine16@yahoo.fr
Cécile Meex
Joseph Gangoué-Piéboji
Raphaël Boreux
Marie-Claire Okomo Assoumou
Pierrette Melin
Patrick De Mol
University of Liège · BEInstitut de Recherches Médicales et d’Etudes des Plantes Médicinales · CMUniversité de Yaoundé I · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is no information regarding the resistance mechanisms of extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae in community setting in Cameroon. The current study aimed to determine the proportion of ESBLs in Enterobacteriaceae isolated in the community and to analyse some risk factors associated with ESBL carriage.

methodsFaecal samples were collected from 208 different outpatients and 150 healthy student volunteers between 3 January and 3 April 2009. Enterobacterial isolates resistant to third-generation cephalosporins were screened for ESBL production by the double-disk synergy test. Presumptive ESBL-producing isolates with positive synergy test were identified by Mass Spectrometry using the BioTyper MALDI-TOF. For such ESBL positive isolates, antibiotic susceptibility was determined by the Vitek 2 system. PCR and sequencing were performed for the detection of different types of ESBL genes in presumptive ESBL-producing isolates. Statistical methods were used for the univariate calculation of risk factors.

resultsDuring the study period, a total of 358 faecal samples were analysed; 58 of such samples (16%) showed an ESBL phenotype and were confirmed by PCR. The proportion of ESBL producers in faecal carriage was statistically different between outpatients and student volunteers (23.1% vs. 6.7%: p < 0.000). According to a univariate analysis, previous use of antibiotics (ciprofloxacin) appeared to be a risk factor for ESBL carriage (p < 0.05).Escherichia coli was the species most frequently isolated among the ESBL producers in outpatients (66.7%) and student volunteers (90%). Isolates showed additional resistance to gentamicin, ciprofloxacin and trimethoprim/sulfamethoxazole but none of them was resistant to temocillin, amikacin or meropenem. Most of the strains (97%) produced a CTX-M group 1 enzymes [CTX-M-15 (98%) or CTX-M-1 (2%)] and the remaining strains produced SHV-12 enzyme (3%).

conclusionsThe use of drugs such as amoxicillin, ciprofloxacin and trimethoprim/sulfamethoxazole does not seem appropriate for empirical treatment because of emerging resistance. The implementation in Cameroon or in other African countries of methods of screening ESBL-producing organisms in routine laboratories is of great importance in order for us to offer patients appropriate treatment and for infection control efforts to succeed.

Indexed as

Adultbeta-Lactamasesbeta-Lactam ResistanceCameroonCarrier StateCephalosporinsCommunity-Acquired InfectionsDrug UtilizationEnterobacteriaceaeEnterobacteriaceae InfectionsFecesFemaleHuman ExperimentationHumansMaleMicrobial Sensitivity Testsbeta-LactamasesCephalosporins

Identifiers

PMID22405322
PMCPMC3329637
OpenAlexW2120432402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.